Daiichi Life has been aggressive in share repurchases, buying back JPY 200 billion of its shares in the fiscal year ended March 2022, JPY 120 billion annually in each of the following two years, and ...

TGCT is a rare, non-cancerous tumour affecting the joints, tendons, or joint tissue. It is linked to a CSF1 gene mutation ...

Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

This study examines the interannual and seasonal variations in the distribution of radioactive materials released from the Fukushima Daiichi Nuclear Power Plant (FDNPP) accident in the surface layer ...

Japanese drugmaker Daiichi Sankyo (TYO: 4568) has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025. Dr Manabe will transition from his current role ...

NEW YORK – AstraZeneca and Daiichi Sankyo have begun treating high-risk non-small cell lung cancer patients with their TROP2-directed antibody drug conjugate Datroway (datopotamab deruxtecan) and ...

As­traZeneca and Dai­ichi Sankyo’s an­ti­body-drug con­ju­gate En­her­tu is now ap­proved to treat a new sub­set of breast can­cer pa­tients with very low lev­els of HER2 … ...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, ...

An AstraZeneca and Daiichi Sankyo drug designed to replace chemotherapy was cleared by US regulators for broader use in late-stage breast cancer patients. The Food and Drug Administration ...